Items where Funder is Amgen Limited ***USE 819922***.

Seligmann, JF, Domingo, E, Fisher, D et al. (17 more authors) (2022) The clinical relevance of tumor RAS/TP53 dual mutation in early and metastatic colorectal cancer (CRC). In: 2022 ASCO Annual Meeting, 03-07 Jun 2022, Chicago, Il, USA and Online.

Williams, C. orcid.org/0000-0002-1574-653X, Seligmann, J.F. orcid.org/0000-0003-4379-6005, Guetter, C. et al. (13 more authors) (2021) Artificial intelligence-assisted immunohistochemical (IHC) evaluation of tumor amphiregulin (AREG) and epiregulin (EREG) expression as a combined predictive biomarker for panitumumab (Pan) therapy benefit in RAS wild-type (wt) metastatic colorectal cancer (mCRC): Analysis within the phase III PICCOLO trial. In: Journal of Clinical Oncology. 2021 Gastrointestinal Cancers Symposium, 15-17 Jan 2021, Online. American Society of Clinical Oncology , p. 111.